Ranolazine
Ranolazine Information

About Ranolazine

Ranolazine is used as an adjunctive anti-anginal treatment for patient with symptomatic stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal tharapies. Ranolazine is a racemic mixture, chemically described as 1-piperazineacetamide, N-(2,6dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (±)-. It has an empirical formula of C24H33N3O4. The mechanism of action of ranolazine's antianginal effects has not been determined. Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure. Ranolazine at therapeutic levels can inhibit the cardiac late sodium current (INa). However, the relationship of this inhibition to angina symptoms is uncertain.

Indications

Ranolazine is primarily indicated in conditions like Angina, Stable angina.

Contraindication

Ranolazine is contraindicated in conditions like Hypokalaemia,Ventricular tachycardia,Severe renal impairment,Hypomagnesaemia,Hepatic impairment,Acute myocardial infarction.

Side Effects

The severe or irreversible adverse effects of Ranolazine, which give rise to further complications include Pulmonary fibrosis, Hematuria, Blurred vision, Tremors, QT prolongation.The signs and symptoms that are produced after the acute overdosage of Ranolazine include Nausea, Vomiting, Confusion, Dizziness, Paresthesia, Syncope.The symptomatic adverse reactions produced by Ranolazine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Vertigo, Headache, Nausea, Vomiting, Tinnitus, Abdominal pain, Dry mouth, Asthenia.

Warnings

Safety not established in pediatric patients. Ranolazine concentration increases 30% and 60% in in patients with mild and moderate hepatic impairment. Take with caution in patients with renal impairment as its concentration increases upto 50% in patients with varying degree of renal impairment. There are no adequate well-controlled studies in pregnant women. Ranolazine should be used during pregnancy only when the potential benefit to the patient justifies the potential risk to the fetus.

High Risk Groups

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.